View Document Preview and Link Document Date: 2014-03-31 07:24:10 Open Document File Size: 801,17 KB Share Result on Facebook
Company Genentech / / Event FDA Phase / / Facility National Cancer Institute of Canada Common Toxicity Criteria / National Cancer Institute of Canada / / IndustryTerm treatment of Dukes’ C colon cancer / therapy for metastatic colorectal cancer / treatment of patients with metastatic breast cancer / treatment of metastatic breast cancer / therapy for Dukes’ C colon cancer / Treatment for Colon Cancer / / MedicalCondition abdominal pain / tumor / Necrotizing enterocolitis / liver metastases / dysesthesia / cancer / cardiomyopathy / colorectal carcinoma / disease / Colorectal Cancer / Dihydropyrimidine Dehydrogenase Deficiency / cardiac failure / Carcinogenesis / dysfunction / neutropenia / nausea / C colon cancer / stomatitis / thrombocytopenia / Metastatic Colorectal Cancer / erythema / hepatic metastases / Colon Cancer / typhlitis / vomiting / numbness / Adjuvant Colon Cancer / Renal Insufficiency / fatigue / Metastatic Breast Cancer / myocardial infarction / coronary artery disease / Hypersensitivity / Diarrhea / angina / granulocytopenia / cardiac arrest / deficiency / Hand-and-Foot Syndrome / metastases / Breast Cancer / paresthesia / anemia / Dehydrogenase (DPD) Deficiency / Syndrome / Hepatic Insufficiency / / MedicalTreatment combination chemotherapy / chemotherapy / adjuvant therapy / / Organization DOSAGE AND ADMINISTRATION / FDA / / / Position physician / General / / Product Phenytoin / paclitaxel / XELODA / fluorouracil / / Technology Geriatrics / Pharmacokinetics / chemotherapy / / URL www.fda.gov/medwatch / / SocialTag 
Microsoft Word - Xeloda USPI Master File December 2013.doc